近来港股生物科技板块依然热潮涌动，8月以来上市的银诺医药、中慧生物等股价屡创新高。在近期陆 续披露半年业绩的生物医药企业中，有稳定的业绩增长预期且具有"真"创新技术的实力派选手，自然成 了市场关注的热点。 在狂犬疫苗领域，身为国内第二大供应商，艾美疫苗在现有主力产品的基础上，布局了迭代无血清狂犬 疫苗、迭代工艺高效价人二倍体狂犬疫苗和mRNA迭代狂犬疫苗，考虑到2030 年中国狂犬病疫苗市场 200亿元的规模，复星国际证券的研报指出：艾美疫苗作为无血清狂犬病疫苗的先行者和 mRNA 狂犬病 疫苗的潜在开发者，有望在这一巨大市场中占据领先地位。 在mRNA技术平台上，艾美疫苗获得中美两国临床批件的重磅大单品，同样有着广阔的市场前景，是潜 在的大爆款疫苗。辉瑞和GSK的呼吸道合胞病毒疫苗于2023年5月份先后获批上市，2023年销售额为 24.6亿美元，GSK的带状疱疹疫苗2023年销售额为43.7亿美元。截至目前，国内尚无RSV疫苗获批上 市，也没有mRNA技术的带状疱疹疫苗上市。 现在的艾美，不仅手握即将兑现的大单品，还拥有充满想象空间的在研大单品。据半年报披露，公司拥 有针对12种疾病领域的20款在研疫苗产 ...

在政策支持、技术创新和市场需求的多重利好因素驱动下，2025年以来港股创新药板块表现显著跑赢大 市。Wind数据显示，2025年以来，有49家医药生物公司涨幅超过100%，在涨幅前10名的公司中，股价 均翻了数倍。前不久，中慧生物登陆港股，又催化了包括疫苗股在内的多只生物医药股的大热行情。 亮眼的股价表现背后，是中国药企的飞速进步。东方证券表示，中国创新药企业正在积极开发源头创新 药物，而"真"创新会带来可持续的出海机会。近期多家投资机构发文表示，创新药行情仍将持续。 8月27日，头部疫苗企业艾美疫苗(06660)发布半年报，2025年上半年，公司营收稳健，随着重磅大单品 进入上市阶段，研发费用降低，经营开支优化。 特别值得关注的是，截至目前，公司拥有针对12种疾病领域的20款在研疫苗产品，管线覆盖全球前十大 疫苗品种，拥有23个临床批件，开展了24项临床试验，1类创新型疫苗达7款。其中，mRNA带状疱疹疫 苗、mRNA呼吸道合胞病毒疫苗同时获批在中美两国开展临床，mRNA技术平台获得国际权威认可。 另外，迭代无血清狂犬疫苗、13价肺炎结合疫苗、迭代工艺高效价人二倍体狂犬疫苗等4款重磅大单品 进入上市冲刺阶段 ...

国内疫苗头部企业艾美疫苗(06660.HK)8月27日发布2025年上半年业绩，公司营收稳健，随着重磅大单 品进入上市阶段，研发费用降低，经营开支优化。四款重磅大单品上市倒计时，即将步入商业化：迭代 无血清狂犬疫苗上市注册申请已获受理；13价肺炎结合疫苗已申请上市注册，已完成现场核查；23价肺 炎多糖疫苗已完成III期临床血清检测，即将进入统计揭盲工作；迭代工艺高效价人二倍体狂犬疫苗目前 处于III期临床阶段，预计2026年提交上市注册申请。 目前，艾美拥有针对12种疾病领域的20款在研疫苗产品，拥有23个临床批件 ，开展了24项临床试验，1 类创新型疫苗7款。其中，三款1类创新型疫苗已获批开展临床 ：EV71-CA16二价手足口病灭活疫苗 （人二倍体细胞）已获批开展I期临床 ；mRNA带状疱疹疫苗 、mRNA呼吸道合胞病毒疫苗，均同时获 批中美两国开展临床试验。出海业务方面，四价流脑多糖疫苗顺利进入非洲市场，并在中亚地区开展注 册；狂犬疫苗首次进入中美洲市场；乙肝疫苗在东南亚积极开展注册流程，甲肝疫苗顺利推进南亚地区 注册。 凭借大单品商业化在即，创新技术的突破性进展，星展银行(DBS Bank)此前发布的 ...

Group 1: Hong Kong Stock Market Highlights - Mixue Group (02097) rose nearly 3% as it launched "Tap to Pay" with Alipay nationwide [1] - Weibo-SW (09898) opened nearly 3% higher post-earnings, with Q1 net profit attributable to shareholders more than doubling year-on-year, driven by membership services [1] - XPeng Motors-W (09868) opened nearly 10% higher and is currently up over 7%, with Q1 performance exceeding market expectations; CEO He Xiaopeng stated profitability is expected in Q4 [1] - Gold concept stocks strengthened, with Chifeng Jilong Gold Mining (6693) up over 3% and several others like Zhaojin Mining and China National Gold rising over 2% [1] - InnoCare Pharma (02577) surged over 15% due to collaboration with NVIDIA on next-generation 800V power architecture, drawing attention to third-generation semiconductors [1] - JD Health (06618) rose over 3% as its "Jingyi Qianxun" medical model is set for a significant upgrade [1] - Smoore International (06969) increased over 3% as Glo Hilo launched in Japan, with positive feedback from trial markets [1] - Gu Ming (01364) rose over 4% to reach a new high, with expectations of over 2,000 new stores this year as it may be included in the Hong Kong Stock Connect next month [1] - Chow Tai Fook (01929) increased over 4% as domestic gold jewelry prices surpassed 1,000 yuan, highlighting gold's value retention [1] - Eucure Biopharma-B (01477) surged over 16% after OT-703 was approved for real-world studies in Hainan Boao [1] - Aimee Vaccine (06660) rose nearly 6% as its mRNA shingles vaccine received clinical trial approvals in both China and the U.S. [1] Group 2: U.S. Stock Market Highlights - Nanwei Semiconductor (NVTS.US) surged over 202% in after-hours trading due to collaboration with NVIDIA on data center power architecture [2] - Pony.ai (PONY.US) initially rose over 5% but closed down 3.3%, despite a 200% increase in Robotaxi revenue [2] - Niu Technologies (NIU.US) rose over 14% with Q1 global vehicle sales increasing over 57% year-on-year [2] - Google (GOOG.US) increased over 5% after launching a new "AI mode" feature for its search engine [2] - Quantum computing stocks saw gains, with Arqit Quantum (ARQQ.US) rising over 21% at one point, and SEALS Q Corp (LAES.US) up over 6% [2] - Canada Goose (GOOS.US) rose nearly 20% as Q4 revenue and adjusted earnings exceeded expectations [2] - CoreWeave (CRWV.US) surged over 14% following a $4 billion agreement with OpenAI, with plans for $23 billion in total spending this year [2] - WeRide (WRD.US) rose over 21% as Q1 Robotaxi revenue significantly increased, with total revenue reaching 72.44 million yuan and a gross margin of 35% [2]

Group 1 - The company has received clinical trial approval for its mRNA shingles vaccine from the National Medical Products Administration, following FDA approval for clinical trials in March 2025, demonstrating the strength of its mRNA technology platform [1] - The mRNA shingles vaccine shows significantly higher specific T cell immunity, specific IgG antibody titers, and fluorescent antibody titers compared to international recombinant subunit vaccine controls in preclinical trials [1] Group 2 - Shingles is caused by the reactivation of the varicella-zoster virus, with an infection rate of over 90% in adults, and the incidence rate is increasing by 2.5% to 5.0% annually [2] - Vaccination against shingles is an effective measure to prevent the disease and its complications, with a target to inhibit the reactivation of the virus [2] Group 3 - Currently, there are no approved mRNA shingles vaccines globally, and the vaccination rate in the target population in China is less than 1%, indicating significant growth potential [3] - The global sales of GSK's shingles vaccine are projected to be approximately $4.31 billion in 2024, with the market size in China expected to reach around RMB 20 billion by 2030 [3] - The company is one of the earliest developers of mRNA vaccines in China, with a mature mRNA vaccine R&D system and a complete industrialization process, enabling rapid commercialization post-clinical trials [3] - The company aims to focus on key technologies of the mRNA platform and accelerate the development and registration of new products to enhance its innovation capability and competitiveness [3]